Drug Store News18h
FDA approves Dong-A ST’s Stelara biosimilar
“This FDA approval indicates global ... a blockbuster drug developed by Janssen Biotech for the treatment of patients with ...
Pharmabiz10h
US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx
US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx: Brussels, Belgium Tuesday, October 15, 2024, 13:00 Hrs [IST] UCB, a global biopharmaceutical compa ...
Managed Healthcare Executive4h
FDA Approves Imuldosa, the Fifth Stelara Biosimilar
Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.
FDA Approves IMULDOSA (ustekinumab-srlf), Accord BioPharma's Biosimilar to STELARA (ustekinumab), for the Treatment of Chronic Inflammatory Conditions
FDA approval of IMULDOSA was granted based on a comprehensive clinical development program. The data showed that IMULDOSA is similar to its reference product STELARA in terms of pharmacokinetic ...
BioSpace2h
Lilly’s Omvoh Beats J&J’s Stelara in Head-to-Head Phase III Crohn’s Disease Trial
At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...
Johnson & Johnson (JNJ) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Conference Call October 15, 2024 8:30 AM ETCompany ParticipantsJessica Moore - Vice President, ...
rheumatologyadvisor4h
Apremilast Enhances Outcomes in Early Oligoarticular PsA
In the phase 4 FOREMOST trial, treatment with apremilast improved both clinical and patient-reported outcomes at week 16 among patients with early oligoarticular PsA.